deltatrials
Recruiting PHASE2 INTERVENTIONAL 2-arm NCT06253611

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer (BIG)

Gut Microbiome Intervention With EXL01 in Combination With Nivolumab and FOLFOX as First-line Treatment for Patients With PD-L1 CPS ≥5 Metastatic Gastric Cancer: A Randomized GERCOR Phase II Study (BIG)

Sponsor: GERCOR - Multidisciplinary Oncology Cooperative Group

Conditions Gastric Cancer
Updated 7 times since 2024 Last updated: Sep 16, 2025 Started: Apr 16, 2024 Primary completion: Sep 30, 2027 Completion: Apr 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Gastric Cancer and is currently actively recruiting participants. GERCOR - Multidisciplinary Oncology Cooperative Group leads this study, which shows 7 recorded versions since 2024 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotNot Yet Recruiting~Jul 2024 – ~Aug 2024 · 31 days · monthly snapshot~Aug 2024 – ~Sep 2024 · 31 days · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotRecruiting~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – ~Oct 2025 · 30 days · monthly snapshot~Oct 2025 – present · 11 months · monthly snapshotRecruiting

Change History

7 versions recorded
  1. Oct 2025 — Present [monthly]

    Recruiting PHASE2

  2. Sep 2025 — Oct 2025 [monthly]

    Recruiting PHASE2

  3. Jul 2025 — Sep 2025 [monthly]

    Recruiting PHASE2

  4. Sep 2024 — Jul 2025 [monthly]

    Recruiting PHASE2

  5. Aug 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

    Status: Not Yet RecruitingRecruiting

Show 2 earlier versions
  1. Jul 2024 — Aug 2024 [monthly]

    Not Yet Recruiting PHASE2

  2. Mar 2024 — Jul 2024 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GERCOR - Multidisciplinary Oncology Cooperative Group
Data source: GERCOR - Multidisciplinary Oncology Cooperative Group

For direct contact, visit the study record on ClinicalTrials.gov .